This review evaluates clinical and experimental articles that have recently been published on the cardioprotective effect of perioperative statin therapy.
Introduction
Three-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, commonly known as statins, have been proven to be highly effective drugs for reducing cholesterol. Randomized, controlled trials of statins consistently demonstrate a substantial reduction in low-density lipoprotein cholesterol (LDL-C). Furthermore, numerous trials evaluating statins have reported a reduction in cardiovascular complications in patients with known or at risk of coronary artery disease [1] [2] [3] [4] [5] [6] [7] [8] .
Besides the lowering of LDL-C however, statins seem to have other, so-called pleiotropic effects, which may, among other effects, stabilize atherosclerotic plaques during surgical procedures [9 ,10] .
The review will focus on recent clinical and experimental evidence of the beneficial effects of statins on vulnerable coronary plaques and their influence on perioperative cardiovascular outcome.
Perioperative myocardial infarction
Although the precise pathophysiology of perioperative myocardial infarction (MI) is not entirely understood, two different methods are thought to be the main contributors to its formation. The first is oxygen supply-demand mismatch, caused by an increase in oxygen demand in the setting of fixed coronary artery stenosis [11, 12] . The second, similar to MIs occurring in the nonoperative setting and which is thought to play a major role in the occurrence of perioperative MIs, is coronary plaque rupture, which leads to thrombus formation and subsequent vessel occlusion [12, 13] . Major contributors to coronary plaque rupture include surgical stress, tachycardia and hypertension [14 ] . Also, in the event of plaque rupture, thrombus growth is not only determined by the thrombogenicity and size of the ruptured thrombus, but also by the number of exposed and activated inflammatory cells, supporting the notion that angiographically small lesions may result in severe stenosis [15] .
Coronary plaques at high risk of rupture are known as vulnerable plaques. The prevalence of vulnerable plaques is high, even in patients without any signs or symptoms. It is impossible, however, to predict the time it will take the vulnerable plaque to become unstable, due to the many factors influencing this process [16] .
Surgery imposes an extra myocardial workload, resulting in mechanical stress, stress-induced inflammation and possible vascular spasms. This can cause vulnerable plaques to become unstable, possibly leading to plaque rupture with resulting thrombus formation, vascular occlusion, myocardial ischemia and eventually MI.
Rupture of a vulnerable plaque is the result of a combination of many factors that can be grouped into two main mechanisms. The first is the combination of intrinsic characteristics of individual plaques that promote plaque instability and the second is the combination of extrinsic forces that influence stress on the plaque, triggering plaque disruption [17 ] . The intrinsic characteristics mainly include plaque morphology. Even though clinical trials have proven that statins positively enhance plaque morphology, it is not likely to have major effects within a few weeks of therapy [18] . Therefore, it seems unlikely that perioperative use of statins reduces the incidence of adverse perioperative cardiovascular complications in this manner. Statins do, however, seem to have early effects on extrinsic factors influencing plaque rupture, that is inflammation and hypercoagulability, which could explain the benefits of perioperative statin therapy.
In an extensive review on vulnerable plaques, Naghavi et al. [19, 20] reported that inflammation is one of the main criteria for defining vulnerable plaques. Generally, it is widely accepted that inflammation is a major force in this process and many studies have focused on inflammation of coronary plaques seeing this main component for vulnerable plaque rupture. Several population-based studies have confirmed the relationship between inflammation markers and the occurrence of cardiovascular events [21, 22] .
Mechanisms of plaque stabilization
Besides lowering cholesterol, statins have other important effects, which are known as its pleiotropic effects. These include the increased expression of endothelial nitric oxide synthase, the generation of reactive oxygen species, the reduction of endothelin-1 production, an improved thrombogenic profile, a reduction in inflammation through reduced expression of cytokines, chemokines, adhesion molecules and a lowering of CRP levels, and the general inhibition of other aspects of the atherosclerotic process [23] [24] [25] [26] [27] [28] [29] .
Statins have been demonstrated to reduce inflammatory activity, measured by significant reductions in CRP, in several clinical studies. Most of these studies found no association between changes in LDL-C or high-density lipoprotein cholesterol and anti-inflammatory activity [30, 31] . In an extensive review, Halcox and Deanfield [32] investigated the evidence for an independent clinical beneficial effect of statins on inflammation. In their review, they clearly point out the discrepancy between the expected findings of statin use and the actual, more pronounced, beneficial effects of statins in large-scale, randomized trials. Besides this, they note that statin use seems to improve outcome in conditions of which LDL-C is not involved in the pathogenesis and shows beneficial effects before a change in lipid levels was detected. Numerous experimental studies have been carried out that support the hypothesis of the anti-inflammatory effects of statin use. In-vitro studies have resulted in abundant evidence of the capacity of statins to interfere with inflammatory pathways [33,34 ,35-40] .
In contrast, Robinson et al. [41] recently published a meta-regression analysis in which no difference was found between the lipid-lowering and pleiotropic aspects of statin therapy. Their findings might be restricted, however, by the criteria used to include studies in the analysis (intervention duration of at least 2 years).
Currently, continuous evidence is being reported on the effects of statins on influencing platelet function, endothelial cell function, vascular smooth muscle cell proliferation, and immunosuppression, all of which help in understanding the different mechanisms of the protective effect of statins [42,43,44 ,45 ,46] .
Effectiveness of perioperative statin use
In the past only one blinded, placebo-controlled, randomized clinical trial evaluating the effects of statin therapy on perioperative cardiovascular complications has been published [47] . In this study, Durazzo et al. randomized 100 patients to treatment with either 20 mg atorvastatin or placebo. Patients received treatment for a total of 45 days and started at least 2 weeks before surgery. One month after surgery patients were advised to either continue or start statin therapy if elevated cholesterol levels were measured. The endpoints in this trial were cardiovascular events, defined as cardiac death, nonfatal MI, stroke or unstable angina pectoris. Patients were followed for up to 6 months after the surgical procedure. After 6 months, the incidence of cardiac events was more than three times higher with placebo (26.0%) than with atorvastatin (8.0%; P ¼ 0.031).
To our knowledge, there have been seven major retrospective trials published in the past, that evaluated the effect of statin therapy on perioperative cardiac complications following cardiac and noncardiac surgery [48] [49] [50] [51] [52] [53] [54] .
All of these studies showed a beneficial effect of statins on perioperative cardiac outcome and emphasized the need for large randomized, controlled trials to confirm their findings.
In the review period three more retrospective studies were published on the effects of statins on perioperative outcome after vascular surgery. O'Neil-Callahan et al.
[55 ] reported a retrospective cohort study, based on hospital notes, in patients undergoing vascular surgery. They evaluated 1163 hospitalizations of 997 patients, who underwent carotid, aortic or lower-extremity vascular surgery in a 2-year period, and noted 571 statin users. Perioperative complication outcomes of this trial included death, myocardial infarction, ischemia, congestive heart failure and ventricular tachyarrhythmias. After adjusting for other significant predictors of perioperative complications, the use of statins showed a significant reduction in the occurrence of cardiac events [odds ratio (OR) 0.52, P ¼ 0.001]. As noted by the authors, however, the highly protective effects of statins in this study was largely accounted for by reductions in myocardial ischemia and congestive heart failure and must be interpreted in the light of the soft endpoints and retrospective nature of the study.
The other two published studies on the effects of statins on perioperative outcome, focused solely on patients undergoing carotid endarterectomy (CEA). Kennedy et al. [56 ] reported a multicenter, retrospective cohort study of 3360 patients undergoing CEA in western Canada between January 2000 and December 2001. Data were obtained from chart records and interpreted by two trained chart reviewers. A total of 815 of the 2031 symptomatic patients and 665 of the 1252 asymptomatic patients were being treated with statins at hospital admission. Perioperative complication outcomes of this trial included in-hospital death, in-hospital ischemic stroke or death and in-hospital cardiac events, defined as a composite of myocardial infarction and unstable angina. In symptomatic patients, they found that statin use was significantly associated with a reduction of in-hospital mortality and in-hospital ischemic stroke or death, even after adjustment for propensity score (adjusted ORs 0.25, CI 0.07-0.90; 0.55, CI 0.32-0.95; 0.87, CI 0.49-1.54, respectively). Statin use was not, however, significantly associated with a reduction of in-hospital cardiac complications in this group. Also, in asymptomatic patients, in which the atherosclerotic plaques may or may not be vulnerable, they found no significant difference in outcome between statin users and nonusers. They concluded that their findings were suggestive of a protective effect of statin therapy in symptomatic patients pretreated at the time of CEA.
McGirt et al. [57 ] reported a retrospective cohort study on all patients undergoing CEA at a large academic medical center from 1994 to 2004. Of the 1566 patients operated on by 13 different surgeons, including 1440 isolated and 126 combined CEA/coronary artery bypass grafting procedures, 657 were statin users. Symptomatic disease was the indication for CEA in 660 cases. Endpoints of this study were perioperative (less than 30 days after surgery) stroke, cranial nerve deficit, myocardial infarction and mortality. After adjusting for all demographics and comorbidities in multivariate analysis, statin use independently reduced the odds of stroke threefold (OR 0.35, P < 0.05) and death fivefold (OR 0.20, P < 0.05). They did not, however, find a significant effect of statins on myocardial infarction.
In these last two studies, patients significantly benefited from statin therapy with respect to mortality and stroke. In both studies a lower nonsignificant incidence of MIs was observed in statin users, compared with nonusers. These nonsignificant results were probably due to the small number of events in these low surgical risk patients.
During the review period, a comprehensive review was published on the cardioprotective role of perioperative statin use. Biccard et al. [58 ] reviewed 11 papers on perioperative statin use, concluding that all of these found an improved postoperative cardiac outcome. Evaluations were done on different aspects of perioperative statin therapy, including timing and duration of administration, therapeutic targets, safety and cost-effectiveness.
Safety of perioperative statin therapy
A major deterrent for perioperative statin therapy has been the fear of statin-induced myopathy and rhabdomyolysis. Perioperatively, there are many factors increasing the risk of statin induced myopathy, such as impaired renal function after major surgery, and multiple drug use during anesthesia [59,60 ,61-63] . Moreover, the use of analgesic agents and postoperative pain may mask signs of myopathy. Failure to detect statin-induced myopathy may then lead to continuous statin use and the subsequent development of rhabdomyolysis and acute renal failure. No studies, however, have been published supporting this assumption, except for a few case reports [64] [65] [66] .
During the review period, one study was published addressing the safety of perioperative statin use. In a retrospective study, Schouten et al. [67 ] studied 981 consecutive patients undergoing vascular surgery from 1998 until 2004. A total of 44 patients with an elevated cholesterol level at preoperative screening were started on statin therapy (acute statin users) with a mean time before surgery of 40 days. A total of 182 patients already taking statin therapy (long-term statin users) continued their statin use. Patients were monitored for symptoms and blood samples were taken on days 1, 3 and 7 and at discharge. Myopathy was defined as creatine kinase (CK) elevations with or without muscle pains. Rhabdomyolysis was considered present if creatine kinase levels were more than 10 times the upper limit of normal. After correcting for cardiac risk factors and clinical risk factors for myopathy, length of surgery remained the only independent predictor for myopathy. No case of rhabdomyolysis was observed.
Conclusion
Past and recent publications indicate a potentially important role for perioperative statin therapy to reduce postoperative cardiac events. The pleiotropic properties of statins lead to plaque stabilization and prevent myocardial ischemia. Although no large randomized clinical trials have yet been published, it seems justifiable to prescribe statins to high-risk patients, for example patients undergoing cardiac or vascular surgery, in anticipation of ongoing conclusive trials. One of these trials is the DECREASE-IV study, in which 6000 moderate to high-risk noncardiovascular surgical patients are randomized for b-blockers, statins, a combination of bblockers and statins or no therapy [68] .
Considering the low incidence of statin-induced myopathy and rhabdomyolysis, the potential benefits of perioperative statin use seem to outweigh the potential hazards. The results of large, randomized clinical trials must be awaited, however, to confirm this.
Acknowledgement
Martin Dunkelgrun is sponsored by the research grant 2003B143 from 'De Nederlandse Hart Stichting' (Dutch Heart Foundation), the Netherlands.
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 460-461). 
